Revolutionizing Cancer Diagnostics

This chapter examines the FDA approval of the Guardian 360 CDX as a companion diagnostic, marking a pivotal shift from invasive biopsies to blood tests for cancer detection. It discusses the implications for HER2 mutated lung cancer patients and the importance of innovative testing solutions like Guarded Reveal for monitoring cancer recurrence.